Detalles de la búsqueda
1.
Toll-like receptor 3 expression in myeloid cells is essential for efficient regeneration after acute pancreatitis in mice.
Eur J Immunol
; 51(5): 1182-1194, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33521935
2.
The neuropeptide receptor subunit RAMP1 constrains the innate immune response during acute pancreatitis in mice.
Pancreatology
; 19(4): 541-547, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31109903
3.
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
JHEP Rep
; 6(6): 101065, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38798717
4.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
J Cancer Res Clin Oncol
; 149(7): 3065-3073, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35864269
5.
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Cancers (Basel)
; 15(17)2023 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686549
6.
Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis.
Cancers (Basel)
; 14(8)2022 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35454881
7.
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
Ther Adv Med Oncol
; 14: 17588359221080298, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35251317
8.
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Cancers (Basel)
; 14(23)2022 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497447
Resultados
1 -
8
de 8
1
Próxima >
>>